Erasca (ERAS) Financials

Erasca logo
$15.11 -0.55 (-3.51%)
Closing price 04:00 PM Eastern
Extended Trading
$15.32 +0.21 (+1.39%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Erasca

Annual Income Statements for Erasca

This table shows Erasca's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-94 -123 -243 -125 -162 -125
Consolidated Net Income / (Loss)
-102 -123 -243 -125 -162 -125
Net Income / (Loss) Continuing Operations
-94 -123 -243 -125 -162 -125
Total Pre-Tax Income
-102 -123 -243 -125 -162 -125
Total Operating Income
-109 -125 -247 -142 -180 -141
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
109 125 247 142 180 141
Selling, General & Admin Expense
7.96 23 33 38 42 39
Research & Development Expense
101 85 214 104 138 102
Other Operating Expenses / (Income)
0.00 17 0.00 0.00 0.00 0.00
Total Other Income / (Expense), net
7.59 2.12 4.65 16 18 16
Interest & Investment Income
0.34 0.19 4.90 17 20 17
Other Income / (Expense), net
7.26 1.93 -0.26 -0.23 -2.16 -0.25
Basic Earnings per Share
($4.83) ($1.85) ($1.99) ($0.83) ($0.69) ($0.44)
Weighted Average Basic Shares Outstanding
21.04M 66.29M 122.02M 150.18M 233.82M 283.53M
Diluted Earnings per Share
($4.83) ($1.85) ($1.99) ($0.83) ($0.69) ($0.44)
Weighted Average Diluted Shares Outstanding
21.04M 66.29M 122.02M 150.18M 233.82M 283.53M
Weighted Average Basic & Diluted Shares Outstanding
21.04M 66.29M 150.59M 151.49M 283.27M 310.80M
Cash Dividends to Common per Share
- - $0.00 $0.00 $0.00 $0.00

Quarterly Income Statements for Erasca

This table shows Erasca's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - - - - - 60
Net Income / (Loss) Attributable to Common Shareholders
-35 -63 -31 -32 -31 -34 -31 -29 -183 -45 -54
Consolidated Net Income / (Loss)
-35 -63 -31 -32 -31 -34 -31 -29 -183 -44 -51
Net Income / (Loss) Continuing Operations
-35 -63 -31 -32 -31 -34 -31 -29 -183 -44 -51
Total Pre-Tax Income
-35 -63 -31 -32 -31 -34 -31 -29 -183 -44 -51
Total Operating Income
-39 -68 -37 -36 -36 -38 -35 -33 -188 -48 -60
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
39 68 37 36 36 38 35 33 188 48 60
Selling, General & Admin Expense
10 12 9.61 9.59 9.66 9.46 10 9.36 11 12 12
Research & Development Expense
29 56 28 26 26 29 24 23 177 36 47
Total Other Income / (Expense), net
3.83 4.58 6.04 3.48 4.66 4.25 3.93 3.51 4.47 3.54 8.19
Interest & Investment Income
3.90 5.04 5.87 5.28 4.74 4.33 3.97 3.57 4.45 3.60 8.26
Other Income / (Expense), net
-0.07 -0.46 0.17 -1.80 -0.08 -0.08 -0.04 -0.05 0.02 -0.06 -0.07
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)
- - - - -0.22 - - - - 0.55 2.94
Basic Earnings per Share
($0.23) ($0.29) ($0.11) ($0.06) ($0.11) ($0.12) ($0.11) ($0.10) ($0.60) ($0.14) ($0.15)
Weighted Average Basic Shares Outstanding
151.16M 217.81M 282.38M 233.82M 283.26M 283.36M 283.68M 283.53M 304.32M 311.34M 344.24M
Diluted Earnings per Share
($0.23) ($0.29) ($0.11) ($0.06) ($0.11) ($0.12) ($0.11) ($0.10) ($0.60) ($0.14) ($0.15)
Weighted Average Diluted Shares Outstanding
151.16M 217.81M 282.38M 233.82M 283.26M 283.36M 283.68M 283.53M 304.32M 311.34M 344.24M
Weighted Average Basic & Diluted Shares Outstanding
173.36M 282.50M 282.73M 283.27M 283.29M 283.67M 283.71M 310.80M 310.98M 349.76M 350.96M

Annual Cash Flow Statements for Erasca

This table details how cash moves in and out of Erasca's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
36 295 -76 -191 -25 6.07
Net Cash From Operating Activities
-33 -80 -103 -101 -109 -95
Net Cash From Continuing Operating Activities
-33 -80 -103 -101 -109 -95
Net Income / (Loss) Continuing Operations
-102 -123 -243 -125 -162 -125
Consolidated Net Income / (Loss)
-102 -123 -243 -125 -162 -125
Depreciation Expense
0.54 0.83 2.64 3.73 3.81 3.11
Amortization Expense
-0.04 0.11 -0.99 -6.95 -9.59 -5.09
Non-Cash Adjustments To Reconcile Net Income
65 35 122 30 56 34
Changes in Operating Assets and Liabilities, net
3.29 7.71 16 -3.19 1.74 -3.26
Net Cash From Investing Activities
-71 -65 -71 -91 -157 100
Net Cash From Continuing Investing Activities
-71 -65 -71 -91 -157 100
Purchase of Property, Plant & Equipment
-0.95 -11 -15 -1.78 -0.06 -0.13
Acquisitions
-38 -7.68 -2.00 -20 -23 -9.50
Purchase of Investments
-99 -106 -134 -314 -403 -151
Sale and/or Maturity of Investments
67 60 80 245 269 261
Other Investing Activities, net
- - - 0.00 -0.16 0.00
Net Cash From Financing Activities
140 439 98 1.30 241 1.10
Net Cash From Continuing Financing Activities
140 439 98 1.30 241 1.10
Issuance of Common Equity
0.00 318 96 0.79 240 0.72
Other Financing Activities, net
3.02 1.94 2.00 0.51 0.84 0.37
Cash Income Taxes Paid
0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Erasca

This table details how cash moves in and out of Erasca's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-16 96 -104 -1.15 2.74 -4.34 4.09 3.58 -27 -4.71 76
Net Cash From Operating Activities
-33 -29 -22 -25 -32 -21 -22 -22 -27 -27 -33
Net Cash From Continuing Operating Activities
-33 -29 -22 -25 -32 -21 -22 -22 -27 -27 -33
Net Income / (Loss) Continuing Operations
-35 -63 -31 -32 -31 -34 -31 -29 -183 -44 -51
Consolidated Net Income / (Loss)
-35 -63 -31 -32 -31 -34 -31 -29 -183 -44 -51
Depreciation Expense
1.00 1.13 0.84 0.83 0.82 0.79 0.76 0.74 0.72 0.72 0.71
Amortization Expense
-2.34 -2.38 -2.52 -2.35 -1.99 -1.50 -1.02 -0.58 -0.75 -0.53 -1.80
Non-Cash Adjustments To Reconcile Net Income
6.85 35 6.64 8.06 6.71 14 7.97 5.75 158 9.61 12
Changes in Operating Assets and Liabilities, net
-3.74 0.53 3.82 1.13 -6.14 0.16 1.26 1.47 -2.33 7.02 7.74
Net Cash From Investing Activities
9.97 -87 -103 23 34 16 26 25 -244 19 -488
Net Cash From Continuing Investing Activities
9.97 -87 -103 23 34 16 26 25 -244 19 -488
Purchase of Property, Plant & Equipment
-0.04 -0.01 -0.01 - -0.08 -0.03 -0.01 -0.01 -0.04 -0.01 -0.08
Purchase of Investments
-44 -100 -192 -67 -11 -57 -42 -42 -253 - -525
Sale and/or Maturity of Investments
54 36 89 90 45 78 71 67 159 20 37
Net Cash From Financing Activities
6.93 212 21 0.80 0.03 0.45 0.04 0.58 245 3.06 598
Net Cash From Continuing Financing Activities
6.93 212 21 0.80 0.03 0.45 0.04 0.58 245 3.36 597
Repurchase of Common Equity
- - - - 0.00 - - - -16 - -39
Issuance of Common Equity
6.91 212 21 0.41 0.00 0.40 - 0.32 259 0.77 633
Other Financing Activities, net
0.02 0.11 0.31 0.40 0.03 0.04 0.04 0.26 1.96 2.60 3.65

Annual Balance Sheets for Erasca

This table presents Erasca's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
125 501 515 395 503 396
Total Current Assets
120 420 444 321 309 286
Cash & Equivalents
65 360 284 93 68 74
Short-Term Investments
53 54 151 219 231 202
Prepaid Expenses
1.29 5.54 8.88 8.33 10 10
Plant, Property, & Equipment, net
1.85 16 25 22 16 13
Total Noncurrent Assets
2.99 65 46 52 177 97
Long-Term Investments
0.00 45 0.00 9.64 142 66
Other Noncurrent Operating Assets
2.99 21 46 43 35 31
Total Liabilities & Shareholders' Equity
125 501 515 395 503 396
Total Liabilities
17 45 103 79 79 71
Total Current Liabilities
14 26 49 26 31 29
Accounts Payable
0.88 4.68 23 2.00 0.47 0.98
Accrued Expenses
12 21 24 20 26 22
Other Current Liabilities
0.88 0.29 1.31 3.97 4.62 5.07
Total Noncurrent Liabilities
3.72 19 54 52 48 42
Other Noncurrent Operating Liabilities
3.72 19 54 52 48 42
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-114 457 412 317 423 325
Total Preferred & Common Equity
-114 457 412 317 423 325
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-114 457 412 317 423 325
Common Stock
1.42 695 894 923 1,191 1,217
Retained Earnings
-115 -238 -481 -606 -768 -892
Accumulated Other Comprehensive Income / (Loss)
0.00 -0.16 -1.04 0.08 0.41 0.63

Quarterly Balance Sheets for Erasca

This table presents Erasca's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
441 419 370 526 529 471 445 420 461 435 999
Total Current Assets
324 306 307 418 330 315 311 300 254 278 655
Cash & Equivalents
139 113 77 173 69 70 66 70 47 43 119
Short-Term Investments
178 184 221 236 250 234 235 218 197 226 525
Prepaid Expenses
6.61 9.30 8.94 9.59 11 10 10.00 12 10.00 9.70 11
Plant, Property, & Equipment, net
24 23 21 18 17 16 15 14 13 12 11
Total Noncurrent Assets
93 90 42 90 182 141 120 106 195 145 332
Long-Term Investments
48 47 0.00 52 144 106 86 74 165 116 304
Other Noncurrent Operating Assets
45 43 42 38 37 35 34 32 30 29 28
Total Liabilities & Shareholders' Equity
441 419 370 526 529 471 445 420 461 435 999
Total Liabilities
78 80 82 75 79 72 73 73 68 73 82
Total Current Liabilities
23 27 30 25 30 25 28 29 27 34 44
Accounts Payable
2.63 3.70 2.63 2.14 2.41 2.26 1.66 3.03 2.16 2.02 3.83
Accrued Expenses
17 19 17 18 23 18 22 21 19 26 35
Other Current Liabilities
3.67 3.82 11 4.29 4.45 4.79 4.71 4.89 5.25 5.44 5.59
Total Noncurrent Liabilities
55 54 51 50 49 46 45 44 41 40 38
Other Noncurrent Operating Liabilities
55 54 51 50 49 46 45 44 41 40 38
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
363 339 288 451 450 400 372 348 394 362 917
Total Preferred & Common Equity
363 339 288 451 450 400 372 348 394 362 917
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
363 339 288 451 450 400 372 348 394 362 917
Common Stock
909 916 930 1,156 1,184 1,198 1,204 1,210 1,470 1,483 2,092
Retained Earnings
-546 -576 -641 -704 -735 -799 -833 -863 -1,076 -1,120 -1,171
Accumulated Other Comprehensive Income / (Loss)
-0.79 -0.58 -0.21 -0.20 1.83 0.63 0.42 0.65 -0.70 -1.25 -4.19

Annual Metrics And Ratios for Erasca

This table displays calculated financial ratios and metrics derived from Erasca's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 121,250,375.00 - - - 283,711,805.00
DEI Adjusted Shares Outstanding
0.00 121,250,375.00 - - - 283,711,805.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -1.01 - - - -0.44
Growth Metrics
- - - - - -
Profitability Metrics
- - - - - -
Net Operating Profit after Tax (NOPAT)
-76 -87 -173 -99 -126 -99
Return On Investment Capital (ROIC_SIMPLE)
- - - -31.28% -29.68% -30.33%
Earnings before Interest and Taxes (EBIT)
-102 -123 -248 -142 -182 -141
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-101 -122 -246 -145 -188 -143
Valuation Ratios
- - - - - -
Leverage & Solvency
- - - - - -
Liquidity Ratios
- - - - - -
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -96 -152 -118 -114 -99
Efficiency Ratios
- - - - - -
Capital & Investment Metrics
- - - - - -
Invested Capital
-11 -2.72 -24 -5.31 -17 -17
Increase / (Decrease) in Invested Capital
0.00 8.56 -21 18 -12 0.35
Book Value per Share
($5.42) $3.77 $3.37 $2.10 $1.50 $1.15
Tangible Book Value per Share
($5.42) $3.77 $3.37 $2.10 $1.50 $1.15
Total Capital
107 457 412 317 423 325
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-119 -459 -436 -322 -440 -342
Capital Expenditures (CapEx)
0.95 11 15 1.78 0.06 0.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-12 -21 -40 -18 -21 -18
Debt-free Net Working Capital (DFNWC)
106 394 396 295 277 258
Net Working Capital (NWC)
106 394 396 295 277 258
Net Nonoperating Expense (NNE)
25 35 70 26 36 26
Net Nonoperating Obligations (NNO)
-119 -459 -436 -322 -440 -342
Total Depreciation and Amortization (D&A)
0.50 0.94 1.65 -3.22 -5.79 -1.98
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($1.85) ($1.99) ($0.83) ($0.69) ($0.44)
Adjusted Weighted Average Basic Shares Outstanding
0.00 121.59M 122.02M 150.18M 233.82M 283.53M
Adjusted Diluted Earnings per Share
$0.00 ($1.85) ($1.99) ($0.83) ($0.69) ($0.44)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 121.59M 122.02M 150.18M 233.82M 283.53M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($1.85) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 66.29M 150.59M 151.49M 283.27M 310.80M
Normalized Net Operating Profit after Tax (NOPAT)
-76 -87 -173 -99 -126 -99
Debt Service Ratios
- - - - - -
Payout Ratios
- - - - - -

Quarterly Metrics And Ratios for Erasca

This table displays calculated financial ratios and metrics derived from Erasca's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - 283,265,716.00 283,287,382.00 283,670,139.00 283,711,805.00 310,799,547.00 310,984,542.00 349,762,035.00
DEI Adjusted Shares Outstanding
- - - - 283,265,716.00 283,287,382.00 283,670,139.00 283,711,805.00 310,799,547.00 310,984,542.00 349,762,035.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - -0.11 -0.12 -0.11 -0.10 -0.59 -0.14 -0.16
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Growth
-8.35% -90.44% -7.22% -10.92% 8.42% 43.99% 10.05% - -409.66% -22.04% -74.12%
EBIT Growth
-4.97% -89.39% -6.81% -10.54% 8.25% 44.01% 6.71% - -426.21% -24.80% -72.32%
NOPAT Growth
-4.93% -88.44% -7.46% -5.43% 8.29% 43.75% 7.24% - -427.40% -24.90% -72.29%
Net Income Growth
-5.48% -98.86% -2.76% -8.52% 11.57% 46.40% 1.88% - -492.39% -30.12% -67.68%
EPS Growth
-4.55% -38.10% 45.00% 70.00% 52.17% 58.62% 0.00% - -445.45% -16.67% -36.36%
Operating Cash Flow Growth
-26.15% -12.45% 7.05% 0.90% 5.10% 29.65% 3.39% - 13.22% -32.82% -51.19%
Free Cash Flow Firm Growth
-7.53% -123.75% 12.40% 68.39% -6.76% 47.79% -31.94% - -465.91% -19.03% -9.29%
Invested Capital Growth
-182.03% -249.79% -189.29% -219.90% -24.78% -58.18% -9.31% - -29.41% -54.59% -114.42%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-14.40% -72.59% 44.24% -0.75% 5.55% -5.55% 10.45% - -478.28% 74.73% -27.76%
EBIT Q/Q Growth
-14.67% -75.35% 45.68% -1.20% 4.82% -7.00% 9.48% - -475.32% 74.62% -24.98%
NOPAT Q/Q Growth
-14.70% -74.47% 45.06% 4.11% 0.23% -7.00% 9.39% - -476.34% 74.66% -24.99%
Net Income Q/Q Growth
-17.90% -80.49% 50.63% -3.31% 3.93% -9.40% 9.64% - -530.55% 75.97% -16.45%
EPS Q/Q Growth
-15.00% -26.09% 62.07% 45.45% -83.33% -9.09% 8.33% - -500.00% 76.67% -7.14%
Operating Cash Flow Q/Q Growth
-34.14% 12.23% 23.18% -9.57% -28.46% 34.94% -5.49% - -26.13% 0.41% -20.07%
Free Cash Flow Firm Q/Q Growth
49.71% -92.87% 57.48% 23.36% -69.85% 5.67% -7.44% - -452.97% 80.16% 1.35%
Invested Capital Q/Q Growth
-74.82% 1.24% -44.75% -28.00% 31.81% -25.19% -0.03% - 9.90% -49.56% -38.75%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Interest Burden Percent
89.98% 92.61% 84.17% 85.92% 86.72% 88.67% 88.52% - 97.63% 92.44% 86.13%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Equity (ROE)
-37.60% -38.90% -40.33% -43.68% -45.82% -31.16% -32.00% - -69.86% -78.25% -48.70%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-37.60% -38.90% -40.33% -43.68% -45.82% -31.16% -32.00% - -69.86% -78.25% -48.70%
Return on Equity Simple (ROE_SIMPLE)
-43.99% -35.09% -35.36% 0.00% -39.45% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-27 -47 -26 -25 -25 -27 -24 -23 -132 -33 -42
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-2.28% -3.82% -1.27% -1.90% -1.70% -1.70% -1.56% - -12.67% -2.79% -1.48%
Return On Investment Capital (ROIC_SIMPLE)
- - - -5.90% -6.24% -7.17% -6.95% -7.02% -33.43% -9.21% -4.54%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-39 -68 -37 -38 -36 -38 -35 -33 -188 -48 -60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-40 -69 -39 -39 -37 -39 -35 -32 -188 -47 -61
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.08 0.91 1.71 1.68 0.97 0.97 1.78 - 12.78 15.74 5.59
Price to Tangible Book Value (P/TBV)
1.08 0.91 1.71 1.68 0.97 0.97 1.78 - 12.78 15.74 5.59
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Financial Leverage
-1.02 -1.01 -1.02 -1.03 -1.03 -1.03 -1.03 - -1.03 -1.05 -1.04
Leverage Ratio
1.24 1.19 1.20 1.21 1.22 1.18 1.19 - 1.18 1.20 1.12
Compound Leverage Factor
1.12 1.10 1.01 1.04 1.06 1.05 1.05 - 1.15 1.11 0.97
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Altman Z-Score
0.42 1.88 4.37 3.67 1.36 0.81 2.75 - 40.55 43.42 36.32
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
10.14 16.79 11.00 9.84 12.35 11.04 10.45 - 9.52 8.29 14.89
Quick Ratio
9.84 16.41 10.62 9.50 11.96 10.68 10.04 - 9.14 8.01 14.63
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-21 -41 -17 -13 -23 -21 -23 -23 -128 -25 -25
Operating Cash Flow to CapEx
-79,169.05% -224,484.62% -448,380.00% 0.00% -38,018.07% -68,436.67% -360,966.67% - -76,063.89% -340,875.00% -41,448.10%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-9.28 -9.16 -13 -17 -12 -14 -14 -17 -15 -22 -31
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-5.99 -6.54 -8.68 -12 -2.30 -5.33 -1.24 0.35 -3.40 -7.91 -17
Enterprise Value (EV)
14 -51 308 269 -23 -27 256 - 4,620 5,313 4,180
Market Capitalization
312 409 771 710 388 360 618 - 5,029 5,697 5,128
Book Value per Share
$1.90 $2.60 $1.59 $1.50 $1.41 $1.31 $1.23 $1.15 $1.27 $1.16 $2.62
Tangible Book Value per Share
$1.90 $2.60 $1.59 $1.50 $1.41 $1.31 $1.23 $1.15 $1.27 $1.16 $2.62
Total Capital
288 451 450 423 400 372 348 325 394 362 917
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-298 -460 -463 -440 -411 -387 -362 -342 -409 -384 -948
Capital Expenditures (CapEx)
0.04 0.01 0.01 0.00 0.08 0.03 0.01 0.01 0.04 0.01 0.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-21 -15 -19 -21 -15 -18 -17 -18 -17 -24 -32
Debt-free Net Working Capital (DFNWC)
276 393 300 277 289 283 271 258 227 245 611
Net Working Capital (NWC)
276 393 300 277 289 283 271 258 227 245 611
Net Nonoperating Expense (NNE)
7.82 16 5.13 7.23 6.03 7.19 6.43 6.27 52 11 9.67
Net Nonoperating Obligations (NNO)
-298 -460 -463 -440 -411 -387 -362 -342 -409 -384 -948
Total Depreciation and Amortization (D&A)
-1.34 -1.24 -1.68 -1.52 -1.16 -0.71 -0.27 0.16 -0.02 0.19 -1.09
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.23) ($0.29) ($0.11) ($0.06) ($0.11) ($0.12) ($0.11) ($0.10) ($0.60) ($0.14) ($0.15)
Adjusted Weighted Average Basic Shares Outstanding
151.16M 217.81M 282.38M 233.82M 283.26M 283.36M 283.68M 283.53M 304.32M 311.34M 344.24M
Adjusted Diluted Earnings per Share
($0.23) ($0.29) ($0.11) ($0.06) ($0.11) ($0.12) ($0.11) ($0.10) ($0.60) ($0.14) ($0.15)
Adjusted Weighted Average Diluted Shares Outstanding
151.16M 217.81M 282.38M 233.82M 283.26M 283.36M 283.68M 283.53M 304.32M 311.34M 344.24M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
173.36M 282.50M 282.73M 283.27M 283.29M 283.67M 283.71M 310.80M 310.98M 349.76M 350.96M
Normalized Net Operating Profit after Tax (NOPAT)
-27 -47 -26 -25 -25 -27 -24 -23 -132 -33 -42
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Erasca (NASDAQ: ERAS) remains a development-stage biotechnology company with no reported revenue throughout the periods provided. Its financial profile is therefore driven primarily by research spending, investment income, equity financing and cash consumption rather than operating sales.

  • Liquidity remains substantial. As of June 30, 2026, Erasca held $42.5 million in cash, $226.2 million in short-term investments and $115.5 million in long-term investments, representing approximately $384.2 million in cash and investments. This compares with total liabilities of only $73.2 million.
  • The balance sheet has limited leverage. Erasca reported no preferred stock and no separately identified debt in the supplied data. Total equity of $361.9 million substantially exceeded total liabilities, while current assets of $278.4 million were more than eight times current liabilities of $33.6 million.
  • Quarterly operating cash burn improved in 2026. Net cash used in operating activities was $27.4 million in the first quarter of 2026 and $27.3 million in the second quarter, compared with $31.6 million in Q1 2025 and $29.2 million in Q2 2024. This suggests better cash conversion despite continued losses.
  • The second-quarter net loss narrowed sharply. Net loss attributable to common shareholders improved to $44.6 million in Q2 2026 from $183.4 million in Q1. The improvement was largely associated with lower operating expenses, particularly research and development costs.
  • Investment income provides a recurring offset to expenses. Interest and investment income was $3.6 million in Q2 2026 and has generally remained between roughly $3.5 million and $5.9 million per quarter across the supplied periods. This benefit is supported by Erasca's large investment portfolio, although it does not replace operating revenue.
  • Recent investment activity has been unusually volatile. Q1 2026 included a $150.0 million acquisition and $253.2 million of investment purchases, while Q2 2026 generated $19.5 million from investment sales or maturities. These transactions materially affect reported cash movements and make quarter-to-quarter cash trends less representative of underlying operations.
  • Research and development spending is inconsistent. R&D expense ranged from approximately $24 million to $29 million per quarter during much of 2023 and 2025, increased to $55.5 million in Q2 2024, surged to $177.3 million in Q1 2026, and then fell to $35.9 million in Q2 2026. Investors should determine whether the Q1 spike was a one-time item or signals a higher ongoing development budget.
  • Erasca continues to report no revenue and substantial operating losses. Revenue was listed as zero in every income statement provided. Operating losses were approximately $47.6 million in Q2 2026 and $187.9 million in Q1, following losses in every prior quarter shown.
  • Operating cash flow remains negative every quarter. Erasca has not generated positive operating cash flow in the supplied four-year period. Continued clinical development will therefore require the company to consume its existing liquidity or raise additional capital.
  • Shareholder dilution is an ongoing concern. Weighted-average basic shares increased from approximately 150.2 million in Q4 2023 to 311.3 million in Q2 2026. The company also raised $258.8 million through common-equity issuance in Q1 2026, while financing activities contributed only $3.1 million in Q2, indicating continued reliance on equity markets to fund operations.

Overall, Erasca's financial strength is its sizeable investment portfolio and relatively low liabilities, which provide meaningful near-term funding capacity. However, the company has no commercial revenue, recurring operating losses and persistent cash burn. The key investor question is whether its clinical programs can eventually produce revenue before the company needs to conduct additional, potentially dilutive financings.

11/16/26 10:05 PM ETAI Generated. May Contain Errors.

Erasca Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Erasca's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Erasca's net income appears to be on a downward trend, with a most recent value of -$124.55 million in 2025, falling from -$101.66 million in 2020. The previous period was -$161.65 million in 2024. View Erasca's forecast to see where analysts expect Erasca to go next.

Erasca's total operating income in 2025 was -$140.91 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $140.91 million

Over the last 5 years, Erasca's total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

In the past 13 quarters, Erasca's cash and equivalents has ranged from $42.54 million in Q2 2026 to $172.80 million in Q2 2024, and is currently $118.96 million as of their latest financial filing in Q3 2026.

Erasca had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2020.

Over the last 5 years, Erasca's book value per share changed from -5.42 in 2020 to 1.15 in 2025.



Financial statements for NASDAQ:ERAS last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners